Table 2. Prognostic factors for CSS in WDTC patients with distant metastasis.
| Characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| 5-year CSS, % | 10-year CSS, % | P value | HR (95% CI) | P value | ||
| Age at distant metastasis | 0.055 | |||||
| <55 years (n=22) | 92 | 92 | Reference | |||
| ≥55 years (n=35) | 88 | 36 | 1.54 (0.15–15.50) | 0.714 | ||
| Sex | 0.333 | |||||
| Female (n=41) | 100 | 68 | ||||
| Male (n=16) | 70 | 35 | ||||
| Diagnosis | 0.094 | |||||
| Papillary carcinoma (n=48) | 92 | 62 | Reference | |||
| Follicular carcinoma (n=9) | 100 | 33 | 0.95 (0.17–5.26) | 0.950 | ||
| Lateral lymph node metastasis | 0.142 | |||||
| Absent (n=23) | 89 | 44 | ||||
| Present (n=34) | 90 | 68 | ||||
| Bone metastasis | 0.002 | |||||
| Absent (n=37) | 100 | 90 | Reference | |||
| Present (n=19) | 75 | 28 | 10.24 (1.25–83.74) | 0.030 | ||
| RAI | 0.001 | NA† | ||||
| Responsive (n=34) | 100 | 100 | ||||
| Refractory (n=23) | 80 | 28 | ||||
| Onset time of distant metastasis | 0.004 | |||||
| Synchronous (n=28) | 86 | 61 | Reference | |||
| Metachronous (1–5 years) (n=18) | 100 | 80 | Reference | |||
| Metachronous (≥5 years) (n=11) | 80 | 20 | 5.20 (1.01–26.63) | 0.048 | ||
| Tg doubling time‡ | 0.008 | |||||
| 0–3 years (n=25) | 80 | 49 | ||||
| Other (n=20) | 100 | 100 | ||||
| De novo anti-Tg antibody | 0.088 | |||||
| Absent (n=49) | 91 | 75 | ||||
| Present (n=8) | 83 | 22 | ||||
| BRAF V600E | 0.827 | |||||
| Absent (n=26) | 92 | 65 | ||||
| Present (n=31) | 87 | 48 | ||||
| RAS mutation | 0.208 | |||||
| Absent (n=47) | 87 | 64 | ||||
| Present (n=10) | 100 | 40 | ||||
| TERT promoter mutation | 0.435 | |||||
| Absent (n=30) | 92 | 73 | ||||
| Present (n=27) | 87 | 51 | ||||
| Coexistent mutations | 0.474 | |||||
| TERT promoter + (BRAF or RAS) (n=22) | 83 | 49 | ||||
| Other (n=35) | 94 | 72 | ||||
†, cancer-specific death has not happened to RAI-responsive patients; ‡, we excluded 12 patients with anti-Tg antibodies (n=8) or less than four data of serum Tg under TSH suppression (n=4). WDTC, well-differentiated thyroid carcinoma; CSS, cancer-specific survival; HR, hazard ratio; CI, confidence interval; RAI, radioactive iodine; NA, not available; Tg, thyroglobulin.